

Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering Number of Hong Kong Offer Shares Number of International Offer Shares

Maximum Offer Price

23,937,000 H Shares (subject to the Over-allotment Option)
2,394,000 H Shares (subject to adjustment)
21,543,000 H Shares (subject to adjustment and the Over-allotment Option)
HK\$24.79 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) RMB1.00 per H Share

Nominal value

全球發售

全球發售的發售股份數目 23,937,000股H股(視乎超額配股權行使與否而定)

香港發售股份數目 國際發售股份數目

23,394,000股H股(可予調整) 21,543,000股H股(可予調整及視乎超額配股權行使與否而定) 每股H股24.79港元,另加1%經紀佣金、0.0027%證監會交易徵費及 0.005%聯交所交易費(須於申請時以港元繳足,多繳股款可予退還) 最高發售價

每股H股人民幣1.00元 股份代號

Application Form 申請表格

Please read carefully the prospectus of Shanghai Bio-heart Biological Technology Co., Ltd. (the "Company") dated December 13, 2021 (the "Prospectus") (in particular, the section on "How to Apply for Hong Kong Offer Shares" in the Prospectus) and the guide on the back of this Application Form before completing this Application Form. Terms defined in the Prospectus have the same meaning when used in this Application Form unless defined herein.

in the Prospectus have the same meaning when used in this Application Form unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Imited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKSCC"), the Securities and Futures Commission of Hong Kong ("SFC") and the Registrar of Companies in Hong Kong take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, the Prospectus and the other documents specified in the section headed "Documents Delivered to the Registrar of Companies in Hong Kong and Available on Display – Documents Delivered to the Registrar of Companies will be the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The SFC and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Vour attention is drawn to the paragraph headed "Personal Data" in the section headed "How to Apply for Hong Kong

any of mess accuments.

Our attention is drawn to the paragraph headed "Personal Data" in the section headed "How to Apply for Hong Kong Offer Shares – 6. Applying through CCASS eIPO Service" in the Prospectus which sets out the policies and practices of the Company and its H Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

traumace (Unapier 400 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The information contained in this Application Form is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States of business of District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares mentioned herein have not been, and will not be, registered under the U.S. Securities Act and applicable U.S. state securities laws.

Ho Offer Shares may not be offered or sold in the United States are not provided to the solicitation of the and applicante U.s. state securities taws.

The Offer Shares may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. No public offering of the securities will be made in the United States.

The Application requirements of the U.S. Securities Act. No public offering of the securities will be made in the United States. This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form and the Prospectus in whole or in part in anuathorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions. The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed "Structure of the Global Offering — The Hong Kong Public Offering Reallocation" in the Prospectus. In particular, the Sole Global Coordinator may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering to 4,788,000 Offer Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 4,788,000 Offer Shares, representing approximately 20% of the Offer Shares initially available under the G

in the Prospectus.

If the number of Shares validly applied for in the Hong Kong Public Offering represents (i) 15 times or more but less than 50 times, (ii) 50 times or more but less than 50 times, (ii) 50 times or more but less than 100 times, and (iii) 100 times or more, of the number of Hong Kong Offer Shares available under the Hong Kong Public Offering, will be increased to 7,182,000 (in the case of (ii)), 575,000 (in the case of (iii)), and 11,968,500 Offer Shares (in the case of (iii)), respectively, representing approximately 30%, 40%, and 50% of the total number of Offer Shares (in that it is a state of the Global Offering, respectively (before any exercise of the Over-alloment Option). Further details of the reallocation are stated in the paragraph headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation" of the Prospectus.

Shanghai Bio-heart Biological Technology Co., Ltd.

Sole Sponsor
Sole Global Coordinator
Sole Bookrunner
Sole Lead Manager
Hong Kong Underwriter

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the CCASS Operational Procedures for White Form eIPO applications submitted via Banks/Stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of the/each underlying applicant to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- $\begin{array}{l} \textbf{enclose} \ payment \ in \ full \ for \ the \ Hong \ Kong \ Offer \ Shares \ applied \ for, \ including \ 1\% \ brokerage \ fee, \ 0.0027\% \ SFC \ transaction \ levy \ and \ 0.005\% \ Stock \ Exchange \ trading \ fee; \end{array}$
- confirm that the underlying applicant(s) has/have undertaken and agreed to accept the Hong Kon Shares applied for, or any lesser number allocated to such underlying applicant(s) on this applicant
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor otherwise participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the So Global Coordinator in deciding whether or not to make any allotment of Hong Kong Offer Shares response to this application, and that the underlying applicant(s) may be prosecuted if he/shc/they made false declaration;
- authorize the Company to place the name(s) of the underlying applicant(s) on the register of membe of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to himber/them, and the Company and/or its agents to send any Share certificate(s) (where applicable) by ordinary post at the each underlying applicant's own risk to the address specified in the application instruction of the relevant underlying applicant in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- request that any e-Refund payment instructions be despatched to the application the applicant(s) had paid the application monies from a single bank account;
- the applicant(s) had paid the application monies from a single bank account;

 request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple
 bank accounts to pay the application monies and is send any such refund cheque(s) by ordinary post at
 that/each underlying applicant's own risk to the address stated on the application in accordance with the
 procedures prescribed in this Application Formand in the Prospectus;

 confirm that the/each underlying applicant has read the terms and conditions and application procedures
 set out in this Application Form and in the Prospectus and in the designated website at www.eipo.com.hk.
 and agree to be bound by them;
- represent, warrant and undertake (a) that each of the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is not restricted by any applicable laws of Hong Kong or elsewhere from making this application, by any ing any application, monies for, or being allocated or taking up, any Hong Kong Offer Shares, and that each of them was ourside the United States when completing or memory, our dee the United States when completing escribed in puragraph (h)(3) of Rule 902 of Regulation in an offshore transaction (within the meaning of application for, the Hong Kong Offer Shares to or by its application is made would not require the Company, as all escokrunner and the Hong Kong Underwriter or any requirements under any law or regulation (whether side Hong Kong; and ir respective officers or advisers to co not having the force of law) of any te

ion, any acceptance of it and the resulting contract, will be governed by and with the laws of Hong Kong.

Name of signatory

·填寫本中請表格前,請賴期上海百心安生物技術股份有限公司(「本公司)於2021年12月13日刊發的招股實程 招股章程)(尤其是招股章程)如何申請香港發售股份]一節,及刊於本申請表格背面的指引。除非本申請表格另 定義。否則本申請表格所使用的詞請與招股章程所界定者具相同讀義。

關下數請留意招股章程[如何申請香港發售股份 — 6.通過中央結算系統eIPO服務提出申請]一節[個人資料]一段,當中載有本公司及其H股證券登記處有關個人資料及遵守香港法例第486章(個人資料(私認)條例)的政策及慣例。

本申請表格或招股章程所載者概不構成在任何作出有關要約、招攬或出售即屬違法的司法權區內就香港發售股份 提出的出售要約或要約購買的招攬,亦不會於有關司法權區出售任何香港發售股份。本申請表格所藏資料,不得 在或向美國(包括其領土及屬地、美國任何州及哥倫比亞特區)境內直接或開接分發。該等資料不構成或組成在美 國購買或認購證券的任何要約或招攬的一部分。本申請表格所述發售股份並無且不會根據美國證券法及美國適用 州證券法登記。

除非已進行登記或獲豁免遵守美國證券法的登記規定,否則不得於美國提呈發售或出售發售股份。證券不會在美 國公開發售。

在香港公開發售與國際發售之間分配發售股份將受招股章程「全球發售的努 所經調整規限。特別是,獨家全球協調人可將發售股份由國際發售重新。 開發售作出的有效申請。根據聯交所發出的特別信用KEX-GL91-18。 相信作出,則可由國際發售重新分配至香港公開發售的發生人仍數目外 球發售初步可供認聯發售股份約10年,使根據香港公開發售的一個大學的 依根據全球裝售初步可能認觸發售股份約20年。於行便任何超級下股權前 的指示性發售價格範圍下限(即每股發售股份約20-25/产元)。

倘香港公開發售有效申請的股份數目等於機實 50倍;(i)50倍或以上但少於100倍;及(ii))100倍 別增至7,182,000股發售股份(如屬(j)的情況) (ii)的情況),分別相當於根據全球發售初步可來 前)。有關重新分配的進一步詳情觀%和媒歷程

上海百心安生物技術股份有限 獨家保萬人 獨家全球協調人 獨家來頭經辦人 香港包銷商

吾等確認,吾等已(i)遵守《電子公開運作程序規則》以及與吾等就香港公及(ii)閱讀招股章程及本申請表格所該/各相關申請人作出申請,吾等

度照招股章程及本申請表格的條款及條件,並在 貴公司的組織章程細則規限下,申請以下數目的香港 時售股份: 等所申請。2購香港發售股份所需的全數款項(包括1%經紀佣金、0.0027%證監會交易徵數及0.005%聯交所 交易費

開中請人名承諾及同意接納所申請認購的香港發售股份,或該等相關申請人根據本申請獲分配的 查數目的香港發售股份;

及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請或承購或表示有意認購或收取 記作或分配。但括有條件及/或暫定)國際發售的任何發售股份,以及將不會申請或承購或表示有意 國際發售的好何發售股份,亦不會以其他方式參與國際發售;

9台 貴公司和獨家全球協調人將依賴此等聲明及陳述,以決定是否就本申請配發任何香港發售股份, 及他關申請人如作出虛假聲明,可能會遭受檢控;

- **援權** 費公司將相關申請人的姓名/名稱列人 貴公司股東名冊內,作為任何將配發于相關申請人的香港發售股份的持有人,且 读公司及/或其代理可根據本申請表格及招股章程所藏程序將任何股票(如適用)以普通感感方式奇愛到相關申請人亦擔;
- (倘申請人使用單一銀行賬戶支付申請股款)要求將任何電子退款指示發送至申請付款賬戶內;
- 要求任何退款支票以使用多個銀行賬戶支付申請股款的相關申請人為抬頭人,並根據本申請表格及招股章程所述程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址,郵誤風險概由該/各相關申請人派德:
- 確認該/各相關申請人已閱讀本申請表格及招股章程以及指定網站www.eipo.com.hk/所載條款及條件以及申請手續,並同會受其約亩:
- **鳖明、保證及承諾**(a)各相關申請人及相關申請人為其利益提出申請的人士並不受香港或其他地方之任何 適用法律限制提出本申請、支付任何申請股款或獲配發或承購任何香港發售股份,及每名該等人士在填 寫及提交申請時均身處美國境外或屬S規例等902條第6n/3)段所述的人士且會於離岸交易/定義见S規例) 中認購香港發售股份;及(b)向或由相關申請人或為其利益而提出本申請的人士經数或申請認營港發售 股份,不會引致 貴公司,獨家保薦人、獨家全集協調人、獨家與灣管理人及香港包銷商或使等各自的 任何高級職員或顧問須遵從香港以外任何地區的法律或規例(不論是否具法律效力)的任何規定;及
- 同意本申請、任何對本申請的接納以及因而訂立的合約,將受香港法律管轄及按其詮釋。

日期 Capacity

?	
	We, on behalf of the
	underlying applicant(s),
	offer to purchase
	吾等(代表相關
	申請人)要約購買

Total number of Shares 股份總數

Hong Kong Offer Shares on behalf of the underlying applicant(s) whose details are contained in the read only CD-ROM submitted with this application form. 代表相關申請人提出認購的香港發售股份(申請人的詳細資料載於連同本申請表格遞交的唯讀光碟)。

Total		cheque(s)	Cheque number(s)
現夾附合共		張支票	支票編號
are enclosed for a total sum of 總金額為	HK\$ 港元		Name of Bank 銀行名稱

|--|

Name of White Form eIPO Service Provider 白表 eIPO 服務供應商名稱			
Chinese name	White Form eIPO Service Provider ID		
中文名稱	白表eIPO服務供應商編號		
Name of contact person	Contact number	Fax number	
聯絡人士姓名	聯絡電話號碼	傳真號碼	
Address	For broker use 此欄供經紀填寫		
地址	Lodged by 申請由以下經紀遞交		
	Broker no. 經紀號碼		
	Broker's chop 經紀印章		

For bank use 此欄供銀行填寫

GUIDE TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the application form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated. To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **White Form eIPO** Service Providers who may provide **White Form eIPO** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicant(s).

Applicant details of the underlying applicant(s) on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheque(s) you are enclosing together with this Application Form; and you must state on the reverse of each of those cheque(s) (i) your **White Form eIPO** Service Provider ID and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2.

All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "CMB WING LUNG (NOMINEES) LIMITED BIOHEART PUBLIC OFFER" (for White Form eIPO);
- be crossed "Account Payee Only";
- not be post dated; and
- be signed by the authorized signatories of the White Form eIPO Service Provider.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonoured on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application.

The Company and the Sole Global Coordinator have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **White Form eIPO** Service Provider in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

PERSONAL DATA

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "**Ordinance**") came into effect in Hong Kong on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the Shares of the policies and practices of the Company and its H Share Registrar in relation to personal data and the Ordinance.

1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company or its agents and/or its H Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the H Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the H Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for, and/or the despatch of Share certificate(s), and/or the despatch of e-Refund payment instructions, and/or the despatch of refund cheque(s) to which you are entitled.

It is important that holders of securities inform the Company and the H Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the applicants and the holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and e-Refund payment instructions/refund cheque, where applicable, verifying compliance with the terms and application procedures set out in this form and the Prospectus, and announcing results of allocation of the Hong Kong Offer Shares;
- enabling compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of MKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc;
 distributing communications from the Company and its subsidiaries;
- coupiling statistical information and Shareholder profiles:
- compiling statistical information and Shareholder profiles;
 making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable
 the Courpany and the H Share Registrar to discharge their obligations to holders
 of securities and/or regulators and/or any other purpose to which the holders of
 securities may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the H Share Registrar relating to the holders of securities will be kept confidential but the Company and its H Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving bankers and overseas principal share registrars;
- where applicants for securities request deposit into CCASS, HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the H Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Retention of personal data The Company and its H Share

The Company and its H Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access and correction of personal data

The Ordinance provides the holders of securities with rights to ascertain whether the Company or the H Share Registrar holds their personal data, to obtain a copy of those data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the H Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company at its registered office disclosed in the "Corporate Information" section in the Prospectus or as notified from time to time in accordance with applicable law, for the attention of the Company secretary or (as the case may be) the H Share Registrar for the attention of the Privacy Compliance Officer for the purposes of the Ordinance.

By signing this form, you agree to all of the above.

填寫本申請表格的指引

下文提述的號碼乃本申請表格中各欄的編號。

在申請表格欄1簽署及填上日期。僅接受親筆簽名。

簽署人的姓名及代表身份亦必須註明。如要使用本申請表格申請香港發售股份, 閣下必須為名列於證監會公佈的白表eIPO服務供應商名單內可以就香港公開發售提供白表eIPO服務的人士。

2 在欄2填上 閣下欲代表相關申請人申請認購的香港發售股份總數(請填寫數字)。

閣下代其作出申請的相關申請人資料,必須載於連同本申請表格遞交的一個唯讀 光碟格式資料檔案內。

3 在欄3填上 閣下付款的詳細資料。

閣下必須在此欄註明 閣下連同本申請表格夾附的支票數目;並在每張支票的背面註明(i) 閣下的白表eIPO服務供應商編號;及(ii)載有相關申請人申請詳細資料的資料檔案的檔案編號。

此欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付的總金額相同。

所有支票及本申請表格, 連同載有該唯讀光碟的密封信封(如有)必須放進蓋上 閣下公司印章的信封內。

如以支票繳付股款,該支票必須:

- 為港元支票;
- 以在香港開設的港元銀行賬戶開出;
- 顯示 閣下(或 閣下代名人)的賬戶名稱;
- 註明抬頭人為「招商永隆受託代管有限公司 百心安公開發售」(白表eIPO 嫡用);
- 以「只准入抬頭人賬戶」劃線方式開出;
- 不得為期票;及
- 由白表eIPO服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶時不獲兑現 , 閣下的申請可遭拒絕 受理。

閣下有責任確保所遞交的支票上的詳細資料與就本申請遞交的唯讀光碟或資料檔 案所載的申請詳細資料相符。

倘出現差異,本公司及獨家全球協調人有絕對酌情權拒絕任何申請。

申請時繳付的款項將不會獲發收據。

4 在欄4填上 閣下的詳細資料(用正楷填寫)。

閣下必須在此欄填上白表eIPO服務供應商的名稱、編號及地址。 閣下亦必須填寫 閣下營業地點的聯絡人士的姓名及電話號碼及(如適用)經紀號碼及加蓋經紀印章。

個人資料

/田 1 次拟北 佳 蒙 四

個人資料收集聲明 香港法例第486章《個人資料(私院)條例為下條例」)中的主要條文於1996年12月20日在香港生效。此項個人資料板集聲明是同股份申請人及持有人說明本公司及其H股證券登記處有關個人資料及條例方面的政策及慣例。

1. 收集 閣下個人資料的原因

證券申請人或證券登記持有人以本身名義申講證券或轉讓或受讓證券時或要求H 股證券登記處提供服務時、須不時向本公司或其代理及/或其H股證券登記處提 供其最新的準確個人資料

未能提供所要求的資料可能導致 閣下的證券申請被拒絕或延遲,或本公司及/或H股證券登記處無法落實轉讓或提供服務。此舉亦可能妨礙或延遲登記或轉讓 閣下成功申請的香港發售股份及/或寄發股票及/或發送電子退款指示,及/或寄發 閣下應得的退款支票。

證券持有人所提供的個人資料如有任何錯誤,須立即通知本公司及H股證券登記

. 目的

證券申請人及持有人的個人資料可作以下用途使用、持有及/或保存(不論何種 方式):

- 處理 閣下的申請及電子退款指示/退款支票(如適用),核實是否符合本表格及招股章程所載條款及申請手續,以及公佈香港發售股份的分配結果;
- 遵守香港及其他地區的所有適用法律及法規;
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券;
- 存置或更新本公司證券持有人的名册;
- 進行或協助進行簽名核對、任何其他核對或交換資料;
- 確定本公司證券持有人的受益權利,如股息、供股及紅股等;
- 分發本公司及其附屬公司的公司通訊;
- 編製統計資料及股東資料;
- 遵照法律、規則或規例的要求作出披露;
- 透過報章公告或其他方式披露獲接納申請人的身份;
- 披露有關資料以便就權益提出申索;及
- 與上述者有關的任何其他附帶或相關目的及/或使本公司及H股證券登記處 能履行對證券持有人及/或監管機構承擔的責任及/或證券持有人不時同意 的任何其他目的。

3. 轉交個人資料

本公司及H股證券登記處會對證券持有人的個人資料保密,但本公司及其H股證券登記處可以在為達到上述目的或當中任何一種目的之必要情況下,作出彼等認為必要的查詢以確定個人資料的準確性,尤其可能會向、從或聯同下列任何及所有人士及機構披露、獲取或轉交證券持有人的個人資料(無論在香港境內或境外):

- 本公司或其委任的代理,如財務顧問、收款銀行及海外主要證券登記處;
- (如證券申請人要求將證券存於中央結算系統)香港結算及香港結算代理人, 彼等將會就中央結算系統的運作使用有關個人資料;
- 向本公司及/或H股證券登記處提供與其各自業務運作有關的行政、電訊、 電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商;
- 聯交所、證監會及任何其他法定、監管或政府機關;及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構,如其銀行、律師、會計師或股票經紀等。

4. 個人資料的保留 本公司及其H股

本公司及其H股證券登記處將按所收集個人資料的用途所需而保留證券申請人及 持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱及更正個人資料

條例賦予證券持有人權利以確定本公司或H股證券登記處是否持有其個人資料、索取該等資料副本及更正任何不準確之資料。根據條例規定,本公司及H股證券登記處有權就處理任何查閱資料的要求收取合理費用。所有關於查閱資料或更正資料或查詢有關政策及慣例的資料及所持有資料類別的要求,應按照招股章程「公司資料」一節中披露的本公司註冊辦事處或根類別用法律不時通別的助址,向本公司的公司秘書或(視乎情況而定)H股證券登記處就條例所指的私隱事務主任提出。

閣下簽署本表格,即表示同意上述所有規定。

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) and a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by 4:00 p.m. on Thursday, December 16, 2021:

CMB Wing Lung Bank Limited Room 1207-1209, 12/F, CMB Wing Lung Bank Centre, 636 Nathan Road, Kowloon

遞交本申請表格

經填妥的本申請表格,連同適用支票及載有唯讀光碟的密封信封,必須於2021年12月 16日(星期四)下午四時正前,送達下列收款銀行:

招商永隆銀行有限公司 九龍

彌敦道636號 招商永隆銀行中心 12樓1207-1209室